Doctor profile · Federal record
Dr. Samer Al-Shurieki, MD
Gastroenterology Physician (CMS: Gastroenterology) · Pensacola, FL
- NPI 1578546784
- Accepts Medicare
- MIPS 68.1 / 100 · 2023
- 30 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
8333 N Davis Hwy, West Florida Medical Center Clinic PA
Pensacola, FL 325146050
(850) 474-8428
fax (850) 969-2906
Credentials & registration
- NPI registered
- November 2005 — 21 yrs on file
- Profile last updated
- April 18, 2012
- Year of graduation
- 1996 — 30 yrs since
- Specialty taxonomy
- 207RG0100X — NUCC code
- State license (1)
- Florida #ME88870
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1578546784. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
30,721
Distinct HCPCS
10
Medicare allowed
$908,088
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J3380 |
Injection, vedolizumab, 1 mg | 24,900 | 18 | $21 | |
J1745 |
Injection, infliximab, excludes biosimilar, 10 mg | 3,790 | 12 | $33 | |
43239 |
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 336 | 326 | $125 | |
43450 |
Dilation of esophagus | 201 | 192 | $39 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 193 | 180 | $125 | |
45384 |
Removal of polyps or growths of large bowel using a flexible endoscope with electrical cautery | 158 | 158 | $208 | |
96413 |
Administration of chemotherapy into vein, 1 hour or less | 157 | 30 | $123 | |
J7050 |
Infusion, normal saline solution, 250 cc | 156 | 30 | $1 | |
45385 |
Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 116 | 114 | $251 | |
99223 |
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 108 | 107 | $173 |
In context: peer comparison
Among 13 peers in Pensacola Gastroenterology Physician, average services per provider: 279. This provider delivers 110× the peer median.Open Payments
Industry payments received
All-time total
$1,300
Transactions
80
Manufacturers
11
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Abbvie INC. | 36 | $556.94 | |
| Janssen Biotech, INC. | 19 | $269.09 | |
| Regeneron Healthcare Solutions, INC. | 5 | $112.56 | |
| Takeda Pharmaceuticals U.S.A., INC. | 5 | $103.31 | |
| Ironwood Pharmaceuticals, INC | 5 | $86.20 | |
| Phathom Pharmaceuticals, INC. | 4 | $60.12 | |
| Pfizer INC. | 2 | $40.32 | |
| Braintree Laboratories, INC. | 1 | $23.28 | |
| Gilead Sciences, INC. | 1 | $17.49 | |
| Lilly USA, LLC | 1 | $15.81 | |
| Celgene Corporation | 1 | $14.41 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
948
Patients
245
Total drug cost
$112,033
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Pantoprazole Sodium | Generic | 499 | 165 | $9,347 |
| Omeprazole | Generic | 113 | 32 | $1,944 |
| Mesalamine | Generic | 58 | 0 | $33,420 |
| Famotidine | Generic | 38 | 13 | $865 |
| Rabeprazole Sodium | Generic | 30 | 13 | $2,317 |
| Sucralfate | Generic | 30 | 0 | $509 |
| Linzess (Linaclotide) | Brand | 29 | 0 | $17,228 |
| Dicyclomine Hcl | Generic | 23 | 11 | $500 |
| Budesonide Dr (Budesonide) | Brand | 22 | 0 | $5,232 |
| Colestipol Hcl | Generic | 22 | 11 | $1,871 |
Frequently asked questions
What is Dr. Samer Al-Shurieki's medical specialty?
Dr. Samer Al-Shurieki practices Gastroenterology Physician in Pensacola, FL.
Where does Dr. Samer Al-Shurieki practice?
Dr. Samer Al-Shurieki practices at 8333 N Davis Hwy, Pensacola, FL 325146050. Office phone: 8504748428.
What is Dr. Samer Al-Shurieki's NPI?
Dr. Samer Al-Shurieki's National Provider Identifier (NPI) is 1578546784, issued by NPPES.
Does Dr. Samer Al-Shurieki accept Medicare assignment?
Yes. Dr. Samer Al-Shurieki accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Samer Al-Shurieki commonly perform?
Top Medicare-reported procedures in 2023: Injection, vedolizumab, 1 mg (HCPCS J3380); Injection, infliximab, excludes biosimilar, 10 mg (HCPCS J1745); Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope (HCPCS 43239). Source: CMS Medicare Physician & Other Practitioners file.